Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this trial is to collect blood serum from cancer patients with tumors at different disease sites (such as pancreas, head and neck, and breast) prior to and at subsequent points following anti-cancer therapy to discover novel serum markers of response.
| Condition | Intervention |
|---|---|
|
Carcinomas (Including Squamous Cell and Adenocarcinoma) Neoplasms |
Procedure: blood draw |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy |
- Survival analysis and response to anti-cancer therapy [ Time Frame: At each follow-up (3 months, 6 months, 1 year; at discretion of MD) 2- Safety Issue?- No ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
blood
| Estimated Enrollment: | 500 |
| Study Start Date: | January 2002 |
| Estimated Primary Completion Date: | January 2022 (Final data collection date for primary outcome measure) |
This is a blood serum collection study at Stanford University for patients with cancer at a variety of disease sites. The purpose of this study is to collect and store blood serum from patients before, during, and after anti-cancer therapy to find new biomarkers that signal disease or response to anti-cancer therapy. The collection and analysis of these biomarkers may lead to improved diagnostic and treatment therapies for certain cancers in the future. We are also interested in collecting blood serum from healthy individuals such as the spouses, relatives, and friends of cancer patients to obtain healthy controls for comparison
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
cancer patients healthy controls
Inclusion Criteria:- Over age 18, no maximum age limit
- Prior diagnosis of cancer (unless healthy control)
- Karnofsky performance status of greater than 70
- Standard pre-treatment evaluation
- Negative pregnancy test
- Signed informed consent
Exclusion Criteria:- Less than 18 years old
- Patient without cancer (unless healthy control)
Contacts and Locations| Contact: Madeline Graber | (650) 498-7703 | mgraber@stanford.edu |
| United States, California | |
| Stanford University School of Medicine | Recruiting |
| Stanford, California, United States, 94305 | |
| Contact: Jonathan Pai 650-498-7703 jpai2@stanford.edu | |
| Contact: Cancer Clinical Trials Office (650) 498-7061 | |
| Principal Investigator: Albert Koong | |
| Sub-Investigator: James M Ford | |
| Sub-Investigator: Quynh-Thu Le | |
| Sub-Investigator: George Albert Fisher M.D. Ph.D. | |
| Sub-Investigator: Anson W Lowe | |
| Principal Investigator: | Albert Koong | Stanford University |
More Information
No publications provided
| Responsible Party: | Stanford University |
| ClinicalTrials.gov Identifier: | NCT00349830 History of Changes |
| Other Study ID Numbers: | VAR0006, 77923 |
| Study First Received: | July 5, 2006 |
| Last Updated: | February 14, 2013 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Adenocarcinoma Adenocarcinoma, Mucinous Neoplasms Carcinoma |
Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms, Cystic, Mucinous, and Serous |
ClinicalTrials.gov processed this record on May 19, 2013